Bio-Path Holdings, Inc. BPTH
At closeNov 5, 2026, 4:00 PM EST
After hours · Nov 5, 4:00 PM ET
- YTD
- -99.50%
- 1 year
- -99.65%
- Market cap
- 15.09K
- EPS (ttm)
- -1.14
- Shares out
- 4.31M
- Forward P/E
- -0.26
- YTD return
- -99.50%
- 1-year return
- -99.65%
- Volume
- 104
- Avg volume
- 34.60K
- Open
- 0.0001
- Previous close
- 0.0003
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.0999
- Beta
- 0.22
- Price target
- 12.00 (+3999900.0%)
- Earnings date
- Mar 8, 2024
5D 0.0000 (0.00%)
Key statistics
- Enterprise value
- -1.88M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.87M
- Total cash
- 4.01M
- Total debt
- 55.00K
- Return on equity
- -366.18%
- Short % of float
- 2.10%
- 50-day average
- 0.8966
- 200-day average
- 1.90
Analyst view
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 8, 2024
Expected Mar 8, 2024. Consensus EPS estimate -0.37.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -1.02 | -0.87 | +0.15 | +14.71% |
| Aug 15, 2024 | Jun 1, 2024 | -1.54 | -1.16 | +0.38 | +24.68% |
| May 15, 2024 | Mar 1, 2024 | -4.54 | -4.88 | -0.34 | -7.49% |
| Mar 8, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 15, 2023 | Sep 1, 2023 | -6.80 | -6.40 | +0.40 | +5.88% |
| Aug 15, 2023 | Jun 1, 2023 | -10.40 | -10.60 | -0.20 | -1.92% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 8, 2024 | Roth MKM | reit | Buy | Buy |
| Apr 18, 2024 | Roth MKM | reit | Buy | Buy |
| Mar 27, 2024 | Roth MKM | main | Buy | Buy |
About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- biopathholdings.com
News
US Stocks Mixed; NY State Business Activity Rises In February 
US Stocks Higher, Micron Reports Downbeat Sales 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Nasdaq Surges Over 1%; DocuSign Shares Spike Higher
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August 
US Stocks Edge Higher; PepsiCo Cuts 2024 Revenue Outlook 
12 Health Care Stocks Moving In Monday's After-Market Session 
12 Health Care Stocks Moving In Friday's Pre-Market Session - Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Your note
Sign in to keep a note on BPTH — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.32% | 13,598 | 14.14K | Sep 29, 2024 |
| Vanguard Group Inc | 0.31% | 13,502 | 14.04K | Sep 29, 2024 |
| Virtu Financial LLC | 0.29% | 12,325 | 12.82K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.25% | 10,917 | 11.35K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.08% | 3,371 | 3.50K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 2,856 | 2.97K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.31% | 13,502 | 14.04K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.28% | 11,963 | 12.44K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.01% | 485 | 504 | Oct 30, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 1 | 1 | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.00% | 170 | 176 | Oct 30, 2024 |